Phase III ARAMIS Trial Showed Significant Improvement in OS for Patients with Prostate Cancer

The investigation of darolutamide plus ADT in men with non-metastatic castration-resistant prostate cancer indicated a significant improvement in overall survival in this patient population.

Source: CancerNetwork - January 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news